Back
 OJEMD  Vol.3 No.8 , December 2013
One-Time Injection of Parathyrin Increases Glucose Tolerance
Abstract: One-time injection of domestic preparation of bull parathyrin—parathyreoidin (1 U/100g body weight, intramuscular) leads to a significant decrease of the blood glucose level and an increase of the serum calcium level in rats. There is a close negative correlation established between glucose and calcium level (r = ?0.813, P > 0.02). The calcium laktat load (9 mg) per os induces the same changes. There is a functional negative correlation established between glucose levels and total calcium content (r = ?0.997, P < 0.01). It proves that the decrease of the blood glucose level under parathyrin injection is connected with hypercalcaemia. Parathyrin causes the reduction of the dynamics of hyperglycemia under the glucose load per os (30% solution, 1 ml/100g), i.e. parathyrin increases glucose tolerance. Glucose consumption by muscle (diaphragm) and adipose (epididymal) tissues in vivo and in vitro does not alter under parathyrin and it does not affect the stimulating effect of insulin on the process. The combinative effect of parathyrin and calcium channel blockers—isoptin (5 mg/kg, intraperitoneal) or nifedipin (1 mg/kg, intraperitoneal) reveals more intensive and lasting decrease of the blood glucose level in comparison with only parathyrin effect and more reduction of the dynamics of hyperglycemia under the glucose load. Thus, parathyrin decreases the blood glucose level, increases glucose tolerance and does not effect insulin resistance.  
Cite this paper: S. Moisa and A. Nozdrachev, "One-Time Injection of Parathyrin Increases Glucose Tolerance," Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 8, 2013, pp. 293-300. doi: 10.4236/ojemd.2013.38040.
References

[1]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Effect of Calcium-Regulating Hormones and Calcium Channel Modulators on Glucose Consumption by Muscle and Adipose Tissues in Vivo and in Vitro,” Bulletin of Experimental Biology and Medicine, Vol. 148, No. 2, 2009, pp. 171-174. http://dx.doi.org/10.1007/s10517-009-0677-x

[2]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Effect of One-Time Injection of Calcitonin Prepations on Glucose and Calcium Level in Rats of Different Age Groups,” Advances of Gerontoljgy, Vol. 23, No. 1, 2010, pp. 93-97.

[3]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Effect of Calcitonin on the Type of Alimentary Hyperglycemia in Rats of Different Age and Sex,” Advances of Gerontology, Vol. 23, No. 2, 2010, pp. 213-220.

[4]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Calcitonin, a Glucoregulating Hormone,” Vestnik Voenno-Medical Academy, Vol. 4, No. 32, 2010, pp. 188-196.

[5]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Mechanisms of Hyperglycemic Effect of Calcitonin,” Bulletin of Experimental Biology and Medicine, Vol. 150, No. 3. 2011, pp. 320-323.
http://dx.doi.org/10.1007/s10517-011-1132-3

[6]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Calcitonin—Contra-Insulin Hormone,” Advances in Gerontology, Vol. 23, No. 3, 2010, pp. 364-370.

[7]   S. S. Butakova (Moisa), “Effect of Calcitonin and Calcium Channel Blockers on Glucose Metabolism,” Materials of All-Russian Conf. with International Participant Devoted to the 85th Anniversary of Foundation of Institute of Physiology Named by I.P. Pavlov of The Russian Academy of Scienses, Sanct-Petersburg, 2010, p. 40.

[8]   S. S. Butakova (Moisa) and A. D. Nozdrachev, “Calcium Channel Blockers Inhibit the Hyperglycemic Effect of Calcitonin,” Bulletin of Experimental Biology and Medicine, Vol. 152, No. 5, 2012, pp. 553-559.
http://dx.doi.org/10.1007/s10517-012-1573-3

[9]   S. S. Moisa and A. D. Nozdrachev, “One-Time Injection of Calcitonin Induces Glucose Intolerance in Children with the 1st Degree Obesity,” Journal “Health” USA, Vol. 5, No. 6, 2013, pp. 9-13.
http://dx.doi.org/10.4236/health.2013.56A1002

[10]   S. S. Moisa, “Calcitonin Contra-Insulin Action on Glucose Metabolism,” Bulletin of Experimental Biology and Medicine, Vol. 156, No. 8, 2013, pp. 183-185.

[11]   H. Frank and E. Kirberger, “Eine Kolorimetrische Methode zur Bestimmung der ‘Wahren Glucose’ und Galactose in 0.05 rm3,” Blut. Biochem. Ztschr, Vol. 320, 1950, pp. 359-367.

[12]   I. I. Selochnik, A. I. Briskin and E. E. Antonova, “Photoelectrocolorimetric Assay of Calcium Concentration in Serum by the Help of EDTA and Murexide,” Chemical Pharmacological Journal, Vol. 12, No. 10, 1978, pp. 138-140.

[13]   H. S. Kim, S. Yumham, H.-Y. Lee, et al., “C-Terminal Part of AgRP Stimulates Insulin Secretion through Calcium Release in Pancreatic ß RinSmf Cells,” Neuropeptides, Vol. 39, No. 4, 2005, pp. 385-393.

[14]   J. F. Habener, “Pathogenesis of Renal Osteodystrophy— A Role for Calcitonin,” Annual Review of Physiology, Vol. 43, 1981, pp. 211-223.
http://dx.doi.org/10.1146/annurev.ph.43.030181.001235

[15]   W. Wang, E. Lewin and K. Olgaard, “Parathyroid Hormone Is Not a Key Hormone in the Rapid Minute-to-Minute Regulation of Plasma Ca2+ Homeostasis in Rats,” European Journal of Clinical Investigation, Vol. 29, No. 4, 1999, pp. 309-320.

[16]   L. J. Deftos, E. G. Watts, D. H. Copp and J. T. Potts, “A Radioimmunoassay for Salmon Calcitonin,” Endocrinology, Vol. 94, No. 22, 1974, pp. 155-160.

[17]   O. Gedik, S. Akalin and Z. Koray, “Effect of Acute Hypercalcaemia on Glucose Tolerance and Insulin Release in Human Beings,” Acta Endocrinologica, Vol. 94, No. 2, 1980, pp. 196-200.

[18]   J. G. Parthemore and L. J. Deftos, “Calcitonin Secretion in Normal Human Subjects,” The Journal of Clinical Endocrinology & Metabolism, Vol. 47, No. 1, 1978, pp. 184-188. http://dx.doi.org/10.1210/jcem-47-1-184

[19]   S. S. Butakova (Moisa), “Calcitonin, a Modulater of Pancreas Secret Process,” Thesis of Addresses, Institute of Physiology named by I.P. Pavlov of The Russian Academy of Scienses, Sanct-Petersburg, 2008, pp. 26-27.

[20]   E. Panzig, W. Besch and K.-D. Rosenbaum, “The Effect of Potassium, Calcium and Magnesium Concentration on Insulin and Glucagon Secretion of the Perfused Dog Pancreas,” Experimental and Clinical Endocrinology & Diabetes, Vol. 86, No. 1, 1985, pp. 61-68.

[21]   G. K. Zoloev, V. D. Slepushkin, R. A. Yakovleva, et al., “Relationships between the Two-Valency Cationes, the Function of the Insular Apparatus of Pancreas and Calcium-Regulating Hormones under the Alteration of Blood Glucose Level,” Human Physiology, Vol. 10, No. 3, 1984, pp. 450-453.

[22]   A. M. Davalli, E. Biancardi, A. Pollo, et al., “Dihydropyridine—Sensitive and—Insensitive Voltage-Operated Calcium Channels Participate in the Control of GlucoseInduced Insulin Release from Human Pancreatic ß-Cells,” Journal of Endocrinology, Vol. 150, No. 2, 1996, pp. 195-203.

[23]   A. B. Jenkins and L. V. Campbell, “Insulin Secretion and Impaired Glucose Tolerance,” Diabetologia, Vol. 53, No. 10, 2010, pp. 2266-2268.
http://dx.doi.org/10.1007/s00125-010-1801-1

[24]   B. L. Wajchenburg, “B-cell Failure in Diabetes and Preservation by Clinical Treatment,” Endocrine Reviews, Vol. 28, No. 2, 2007, pp. 187-218.
http://dx.doi.org/10.1210/10.1210/er.2006-0038

[25]   A. Mari, A. Tura and A. Natali, “Impared Beta Cell Glucose Sensitivity Rather than Inadequate Compensation for Insulin Resistance Is the Dominant Defect in Glucose Intolerance,” Diabetologia, Vol. 53, No. 4, 2010, pp. 749756. http://dx.doi.org/10.1007/s00125-009-1647-6

[26]   E. A. Ertel, K. P. Campbell, M. M. Harpold et al., “Nomencrature of Voltage-Gate Calcium Channels,” Neuron, Vol. 25, No. 3, 2000, pp. 533-535.
http://dx.doi.org/10.1016/S0896-6273(00)81057-0

[27]   W. O. Wilkinson, M. B. Zemel and N. Moustaid-Moussa, “Modulation of the Sulfonylurea Receptor and Calcium in Adipocyties for Treatment of Obesity/Diabetes: Patent 6569633 USA, МПК 7 GOIN 33/566, GOIN 33/567,” Artesel Science Inc., 2003. No. 09/592421.

 
 
Top